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SIGNIFICANCE
Prurigo nodularis is a rare skin disease characterized by in-
tense pruritus, leading to lack of sleep and reduced quality 
of life. For dermatologists worldwide, treatment of prurigo 
nodularis remains a challenge, as there are no approved 
treatments for the disease and patients are often insuf-
ficiently treated with the existing therapies. This patient- 
based survey examined treatment tendencies and treat-
ment effectiveness, comorbidities, pruritus and quality of 
life in a cohort of patients with prurigo nodularis. Overall, 
topical corticosteroids and ultraviolet B are the most com-
monly used treatments; however, topical corticosteroids 
under occlusion, zinc-dressing treatment and steroid injec-
tion were reported as the most effective treatments.
Prurigo nodularis is a pruritic dermatosis with poor 
treatment options. To describe treatment patterns, co-
morbidities, pruritus, and quality of life a survey was 
administered to 92 patients with prurigo nodularis. A 
total of 52 patients completed the survey. The most 
frequently used treatments were topical corticoste-
roids, which were prescribed to 49/52 patients, with 
positive effect in 13/49. A total of 46/52 patients were 
treated with ultraviolet B, and 9/46 reported a positive 
effect. A positive effect was reported for topical corti-
costeroids under occlusion in 21/40, for zinc dressing 
treatment in 17/37, for steroid injection in 9/14, for 
methotrexate in 5/16, and for thalidomide in 4/12 of 
treated patients. Thirty-six patients reported a Pitts-
burgh Sleep Quality Index >5, indicating poor sleep. 
Patients with prurigo nodularis are severely bothered 
by pruritus negatively affecting quality of life. Various 
treatments are prescribed; most frequently topical 
corticosteroids and ultraviolet B. Surprisingly, patients 
reported topical corticosteroids under occlusion, zinc-
dressing treatment and steroid injection as the most 
effective. 
Key words: prurigo nodularis; Hyde’s disease; pruritus; survey; 
treatment; quality of life.
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Prurigo nodularis (PN) is a subtype of chronic pru-rigo dominated by multiple hyperkeratotic nodules 
with a symmetrical distribution (1, 2). The predominant 
symptom of PN is an intense pruritus, often leading to 
disturbed sleep and reduced quality of life (QoL) (3). PN 
is characterized as a distinct skin disease and is believed 
to be caused by underlying conditions in which itch is 
also part of the symptoms, such as atopic dermatitis, 
neuropathies, and chronic liver and kidney dysfunctions 
(2, 4). Repetitive itching on the skin may start a cascade 
of processes involving the immune system, neurones and 
epithelial cells, causing an urge to repeated scratching, 
known as the itch-scratch cycle (5). Many theories 
about the pathogenesis of PN have been hypothesized, 
including; growth of the peripheral nerves leading to 
hypersensitivity of the nerve endings, increased levels 
of substance P in the small nerve fibres in dermis, and 
interleukin-31 (IL-31) in blood; both being mediators 
of pruritus (6, 7).
For dermatologists, the management of PN is chal-
lenging, due to the lack of understanding of the disease, 
combined with limited treatment options. 
To improve the knowledge of PN, a survey-based 
study was established to investigate demographic cha-
racteristics, comorbidities, commonly used treatments, 
pruritus specification and the effect of these from the 
patient’s perspective. Furthermore, the impact of PN on 
QoL was investigated. 
METHODS
Study approval was obtained from the Danish Data Protection 
Agency (ref. HGH-2017-120, I-Suite: 06038) and The Danish 
Health Authority (ref. 3-3013-2267/1). Patients were identified if 
they were ≥ 18 years of age and had been patients at the Depart-
ment of Dermatology and Allergy, Herlev and Gentofte Hospital, 
University of Copenhagen, Denmark and received a diagnosis of 
PN (DL281) between 2006 and 2016. For all identified patients, 
charts were investigated to ensure that only eligible patients recei-
ved a survey. Patients who had died, moved abroad, or had been 
misclassified with a PN diagnosis were excluded. The survey was 
programmed in REDCap and was sent to patients via email and 
regular post, as a large proportion of patients were elderly. The 
survey comprised 104 questions about PN, including previous 
and present treatments, the effectiveness of treatments assessed 
by the patient, pruritus specification, including visual analogue 
scale (VAS) pruritus, localization and intensity within the last 
month, active underlying dermatological and non-dermatological 
conditions, sociodemographic status, QoL, including Dermatology 
Life Quality Index (DLQI, range 0–30), and quality of sleep, 
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measured by Pittsburgh Sleep Quality Index (PSQI, range 0–21, a 
score ≤ 5 defined as good sleep and > 5 indicating poor sleep). For 
the survey questions on treatments, all responses were validated 
with the registered data in the patient chart, and in cases where a 
mismatch between the survey response and the patient chart data 
were observed, information from the patient file was used. 
Data were registered in REDCap and exported to Microsoft 
Excel (Version 1808) and SPSS (Version 22.0.0.0), where sta-
tistical analyses were performed, and data were presented using 
descriptive statistics or as means with standard deviations (SD). 
RESULTS
Patient characteristics
A total of 132 patients with a diagnosis of PN were iden-
tified. Of these patients, 39 were excluded as they had 
either died, moved abroad, or were misdiagnosed. The 
survey was distributed to 92 eligible patients (mean ± SD 
age 64.4 ± 14.5 years), where 58 (62.4%) were women.
A response was received from 52 (55.9%) patients 
(mean ± SD age 64.4 ± 11.0 years), of whom 35 (67.3%) 
were women and 28 (53.8%) were ≥ 65 years of age. No 
significant difference in age or sex was found between 
responders and non-responders. All patients with PN had 
been diagnosed by a dermatologist. Patients’ sociodemo-
graphic characteristics are shown in Table I. 
Table I. Patients’ sociodemographic characteristics and 
comorbidities (n = 52)
Characteristics n (%)
Age
18–24 years 0 (0)
25–34 years 0 (0) 
35–44 years 3 (5.8)
45–54 years 6 (11.5)
55–64 years 15 (28.8)
≥ 65 years 28 (53.8)
Sex
Male 17 (32.7)
Female 35 (67.3)
Civil status
Married/having a partner 35 (67.3)
Single/divorced/widowed 17 (32.7)
Educational level
Less than high-school   8 (15.4)
High-school or general education 13 (25.0)
College or 2-year degree   5 (9.6)
Bachelor’s degree 14 (26.9)
Graduate degree 9 (17.3)
Other 3 (5.8)
Smoking status
Never 20 (38.5)
Previous 24 (46.2)
Smoker   8 (14.4)
Use of alcohol, glass/week
None 17 (3.7)
1–7 24 (46.2)
8–14 9 (17.3)
15–21 0 (0)
> 21 2 (3.8)
Comorbidities
Dermatological 14 (26.9)
Systemic 9 (17.3)
Neurological 5 (9.6)
Psychiatric 9 (17.3)
Other 13 (25.0)
Mean ± SD duration of PN was 11.6 ± 8.2 years. Twen-
ty-six (50.0%), patients had > 20 nodules and only 10 
(19.2%) had < 6 nodules. The most frequently reported 
localization of PN were legs/feet (92.2%) and arms/hands 
(78.4%), followed by back (47.1%), buttocks/genitals 
(37.3%), chest (35.3%) and head/neck (19.6%).
More than a quarter (26.9%) of the patients had a con-
comitant dermatological disease; 8 (15.4%) had atopic 
dermatitis, which was the most commonly reported 
dermatological disease. 
Regarding other diseases, 23 (44.2%) patients repor-
ted having at least 1 concomitant non-dermatological 
disease; and 9 (17.3%) had a psychiatric disease, which 
was the most commonly reported non-dermatological 
disease (Table I). 
Treatment characteristics
For local treatments, all 52 patients had been treated with 
at least one type of topical treatment. The most commonly 
used were topical corticosteroids. A total of 49 patients 
(94.2%) had been treated with topical corticosteroids; of 
these 13 (26.5%) reported a positive effect on pruritus. A 
total of 40 patients (76.9%) had been treated with topical 
corticosteroids under occlusion; of these 21 (52.5%) re-
ported a positive effect on pruritus. A total of 37 patients 
(71.2%) had been treated with zinc dressing treatment; of 
these 17 (45.9%) reported a positive effect on pruritus. 
A total of 14 patients (26.9%) had been treated with in-
tradermal injection of corticosteroid; of these 9 (64.3%) 
reported a positive effect on pruritus.
For phototherapy, 46 patients (88.4%) had been treated 
with UVB (3 weekly irradiations of narrowband-UVB 
for 8–12 weeks is standard at the department); of these 
9 (19.6%) reported a positive effect on pruritus. 
Only 24 patients (46.2%) had been treated with at least 
one type of systemic treatment. The most frequently 
used systemic treatment was methotrexate (15–20 mg 
weekly). In total, 16 patients (30.8%) had been treated 
with methotrexate; of these 5 (31.3%) reported a posi-
tive effect on pruritus. A total of 12 patients (23.1%) 
had been treated with thalidomide (25–50 mg daily); of 
these 4 (33.0%) reported a positive effect on pruritus; 
however, thalidomide was associated with several side-
effects (Fig. 1).
Pruritus characteristics and impact on quality of life
The patients experienced moderate to severe pruritus on 
the VAS scale (mean ± SD VAS 6.6 ± 2.4). In a majority 
of patients, pruritus occurred at least several times a day 
(65.4%), with the evening (66.7%) and night (41.1%) 
being reported as the most intense hours of pruritus. 
Pruritus characteristics are shown in Table II.
Thirty-nine (75.0%) responded that pruritus had a 
negative effect on their QoL, mean ± SD DLQI was 
7.0 ± 5.6, indicating an overall moderate effect on QoL. 
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Fourteen patients (26.9%) did not participate in social 
activities and were more absent from work compared 
with colleagues, or had to retire from work due to their 
disease. For sleep-quality, 10 patients (19.2%) used sleep 
medication at least once a month and mean ± SD PSQI 
was 6.2 ± 2.0, indicating poor sleep.
DISCUSSION
Main findings and interpretation
This study found that the majority of patients with PN 
were elderly (53.8% were ≥ 65 years of age) and female 
(67.3%). In more than half of the patients (57.7%) we 
identified at least one underlying condition; however, 
patients had a wide range of conditions, with the most 
commonly reported being atopic dermatitis and psychia-
tric conditions. This study found that various treatments 
are prescribed to patients with PN, but, overall, the ef-
fectiveness of treatments is poor. Corticosteroids under 
occlusion, zinc dressing treatment, steroid injections, 
methotrexate and thalidomide were reported as the most 
effective treatments; however, results of steroid injec-
tions, methotrexate and thalidomide should be considered 
with caution, as the number of patients treated was small. 
In general, patients with PN are negatively affected by 
their disease, mainly due to severe pruritus. 
In an EADV Task Force Pruritus survey, 73% of 
members considered PN to be a distinct condition (8). 
When looking at underlying conditions, the current study 
found that 58% of patients had at least one underlying 
condition, with the most common, at 15%, being atopic 
dermatitis. Likewise, Iking et al. (9) found a similar pre-
valence of atopic dermatitis in a cohort of 108 patients 
with PN (18% vs. 15%), which has also been described 
elsewhere (4). In the study by Iking et al., 87% of patients 
had an underlying condition; however, these data were 
extracted from a database and not entirely self-reported, 
which may explain the difference from our findings. Also, 
in a recent study by Boozalis et al. (4), it was found that 
PN was associated with numerous systemic conditions, 
0
5
10
15
20
25
30
35
40
45
50
Positive Discrete effect Negative (uacceptable side-effects) No effect
Fig. 1. Prescribed therapies and patient-assessed evaluation of treatment in a cohort of patients with prurigo nodularis. The y-axis represents 
number of treated patients. The x-axis represents various treatments. Colour-bars represent evaluation of treatment. Patients reporting treatment effect 
as: “positive” blue; “discrete effect” orange; “negative effect” grey; “no effect” yellow.
Table II. Pruritus characteristics in patients with prurigo nodularis; 
localization of pruritus, day- and night-time course of pruritus 
(*multiple answers possible), frequency of pruritus and quality of 
pruritus (*multiple answers possible) 
Characteristics n (%)
Pruritus localization
Single area 16 (31.3)
Multiple areas 29 (56.9) 
Whole body   6 (11.8)
Pruritus peak hours*
Morning 13 (25.0)
Afternoon   7 (13.7)
Evening 34 (66.7)
Night 21 (41.1)
All day 12 (25.5)
Pruritus frequency
Never 1 (1.9)
Monthly 0 (0.0)
Weekly 1 (1.9)
Once a day 5 (9.6)
Many times a day 34 (65.4)
Most of the day 11 (15.4)
Pruritus frequency*
Stinging/prickly 36 (72.0)
Burning 19 (38.0)
Pain 16 (32.0)
Warmth 21 (42.0)
Biting 11 (22.0)
Electrical 2 (4.0)
Cold 0 (0.0)
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such as HIV, chronic kidney diseases and diabetes. We 
were not able to recognize these findings in our study, 
which could be explained by ethnic differences, as our 
patient group was primarily Caucasian. 
In the literature it has been discussed whether psychia-
tric conditions are more common in patients with PN and 
whether psychological distress could lead to picking of 
the skin, thereby inducing PN (1). It was found that 17% 
of patients had a psychiatric condition; of these 10% had 
depression. Similarly, in 2018, Jørgensen et al. (3) found, 
in a cohort of 877 patients with PN, 8.5% had depression, 
thus PN seems more often to be associated with having 
a psychiatric condition compared with the background 
population (10, 11). 
It is well established that scratching behaviour may 
play a role in triggering the itch-scratch cycle (1, 3, 12). 
This emphasizes the importance of optimizing treatment 
for patients with pruritic diseases, such as atopic derma-
titis, to stop patients commencing continuous scratching. 
Indeed, breaking the itch-scratch cycle may be an im-
portant treatment goal for patients with PN. In support 
of this, we found positive reporting in a large proportion 
of patients (46.9–52.5%), who had used corticosteroids 
under occlusion or zinc dressing treatment; ideally these 
should be considered as a first-line treatment. 
Interestingly, this study found that the most commonly 
used treatments were topical corticosteroids and UVB; 
however, only a minor group of the patients reported 
these to have a positive effect (26.5% and 19.6%). This 
indicates that topical corticosteroids under occlusion 
should be tried first. In patients presenting only a few 
nodules intradermal injection of steroid may be benefi-
cial, as a majority of treated patients (64.3%) reported 
this to have a positive effect. 
In the literature immunosuppressants and gabapentin 
have been described as effective systemic therapies for 
pruritus (13, 14). This was also found in the EADV 
Task Force Pruritus survey, in which 27% and 17% of 
physicians reported immunosuppressants and gabapentin 
as the most effective therapies (8). 
In the current study, only 6 patients had been trea-
ted with gabapentin (11.5%), thus the number is too 
small to evaluate the effect of these. Nearly one-third 
of patients (31.3%) considered methotrexate to have a 
positive effect, indicating that methotrexate should be 
considered at an early stage of the disease. In line with 
this, a recent review concluded that methotrexate was 
able to significantly reduce pruritus in patients with PN 
(15). Although a large proportion of patients (33.0%) 
treated with thalidomide reported this to have a positive 
effect, it should be prescribed with caution. In a study 
by Andersen & Fogh (16), thalidomide reduced pruritus 
in 32 of 42 (76.2%) treated patients with PN, but in 25 
patients (59.5%) peripheral neuropathy was observed. 
Furthermore, thalidomide has a poor safety profile 
and is associated with several severe conditions, such 
as thromboembolisms, bone-marrow suppression and 
teratogenicity (16, 17). 
As reported in other studies (3), patients with PN were 
found to carry a great burden of disease with a negative 
impact on everyday life, social activities and sleep, which 
highlights the importance of offering these patients the 
most effective on-hand treatment. Although we found 
that corticosteroids under occlusion and zinc dressing 
treatment could decrease pruritus, there is still a need 
for new treatments, as many patients are not sufficiently 
treated with the existing treatments. A clinical trial ex-
ploring the use of neurokinin-1-receptor antagonist has 
recently shown that it has an effect and a few case reports 
of patients with PN treated with dupilumab have shown 
promising results (18–20). Furthermore, nalbuphine 
(NCT02174432) and nemolizumab (NCT03181503) 
have been shown to be able to reduce pruritus in other 
dermatosis (21, 22), and both are currently being investi-
gated as potential treatments for PN. 
Strengths and limitations
This patient-based survey includes both the treatment 
patterns, the effectiveness of existing treatments and the 
continuous needs from the patient’s perspective. This 
study was established, containing detailed questions on 
therapies used, pruritus characteristics, comorbidities, 
and QoL, in order to retrieve a better understanding of 
PN, which has been warranted by the EADV Task Force 
Pruritus (8). It is hoped that this can guide physicians to 
improve the management of PN with the existing treat-
ments. Secondly, all patient charts were investigated 
by a physician to ensure that only patients with correct 
diagnosis were included. Also, patient answers on treat-
ment were validated. Thirdly, we identified, although the 
sample size was small, 92 patients with PN. However, 
the response rate was nearly 60%, which should be con-
sidered as a satisfactory result, as this is a vulnerable and 
elderly group of patients. 
Limitations of this study are; a large part of the in-
formation is based on surveys, which is likely to induce 
recall bias. Although we found no difference in age and 
sex between groups of responders and non-responders, 
surveys often increase risk of selection bias, as patients 
with severe disease may be more prone to respond. More-
over, this was a descriptive study with no control group. 
An improvement would be to compare the patient group 
with patients who have other dermatological diseases, 
as has been done by Steinke et al., where patients with 
PN were found to have a decreased QoL compared with 
other pruritic dermatological diseases (23). 
Conclusion
This study found that patients are severely affected by PN, 
especially due to severe pruritus. Many patients are treated 
with numerous treatments, including topical-, photo- and 
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
5/5Prurigo nodularis and treatment patterns
Acta Derm Venereol 2020
systemic therapy; however, for a large group of patients 
the existing treatments are not able to reduce pruritus. 
Patients considered the most effective treatments to be 
corticosteroids under occlusion and zinc dressing treat-
ment, steroid injection, methotrexate and thalidomide. 
In conclusion, these results emphasize the need for new 
therapies to improve the management of PN.
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